Aldeyra Therapeutics
NASDAQ: ALDXLexington, US · Delaware corporation · 1 known investors
Aldeyra develops medicines for immune-mediated diseases, with product candidates aimed at inhibiting inflammatory cells linked to ocular and systemic conditions. The company advances investigational therapies through late-stage clinical trials, focusing on immunological modulation to address unmet treatment needs.
Founders & leadership
TC
Todd C. BradyExecutive
ST
Stephen TulipanoExecutive
SL
Scott L. YoungExecutive
Board
JI
BB
Ben BronsteinBoard director
GP
Gary PhillipsBoard director
NW
Neal WalkerBoard director
MJ
Martin J. JoyceBoard director
CB
C. Boyd ClarkeBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$19.8M disclosed across 3 rounds · 2015–2019
▶$10MraisedFeb 2019 · 37 investors · BiotechnologyRule 506(b)
▶$10MraisedFeb 2019 · 37 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard DouglasDirector
- Neal WalkerDirector
- Martin J. JoyceDirector
- Jesse I. TreuDirector
- Todd BradyExecutive Officer, Director
- David L. ClarkExecutive Officer
- Ben BronsteinDirector
- David McMullinExecutive Officer
- Gary PhillipsDirector
- Stephen MachathaExecutive Officer
- Joshua ReedExecutive Officer
- Offering amount
- $25M
- Amount sold
- $10M
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedFeb 2015 · 1 investors · BiotechnologyRule 506(b)
▶$2MraisedFeb 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jesse I. TreuDirector
- Neal WalkerDirector
- Stephen TulipanoExecutive Officer
- Scott YoungExecutive Officer
- C.Boyd ClarkeDirector
- Ben BronsteinDirector
- Martin J. JoyceDirector
- Gary PhillipsDirector
- Todd C. BradyExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $2M
- First sale
- Jan 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.8MraisedJan 2015 · 16 investors · BiotechnologyRule 506(b)
▶$7.8MraisedJan 2015 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Todd C. BradyExecutive Officer, Director
- Ben BronsteinDirector
- Stephen TulipanoExecutive Officer
- Gary PhillipsDirector
- Neal WalkerDirector
- Jesse I. TreuDirector
- Scott L. YoungExecutive Officer
- Martin J. JoyceDirector
- C. Boyd ClarkeDirector
- Offering amount
- $18.4M
- Amount sold
- $7.8M
- First sale
- Jan 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Aldeyra Therapeutics do?
- Aldeyra develops medicines for immune-mediated diseases, with product candidates aimed at inhibiting inflammatory cells linked to ocular and systemic conditions. The company advances investigational therapies through late-stage clinical trials, focusing on immunological modulation to address unmet treatment needs.
- Who are Aldeyra Therapeutics's investors?
- Aldeyra Therapeutics's investors include Domain Associates.
- How much funding has Aldeyra Therapeutics raised?
- Aldeyra Therapeutics has disclosed $19.8M raised across 3 rounds.
- Where is Aldeyra Therapeutics headquartered?
- Aldeyra Therapeutics is headquartered in Lexington, US.